Moderna announces positive results for its anti-Covid vaccine in 6-11 year olds

the essential Clinical trials conducted on more than 4700 participants “demonstrate a strong immune response in this group of children one month after the second dose” , with “robust” antibody levels detected, Moderna said in a statement.

Moderna announced this Monday 25 October to have obtained positive results for its vaccine against the Covid – 19 in children 6 to 11 years, data the company plans to submit to regulators around the world “in the short term” for clearance.

Clinical trials conducted on more than 4700 participants “demonstrate a strong immune response in this group of children one month after the second dose”, with “robust” antibody levels detected, Moderna said in a statement.

The vaccine further exhibits a “favorable safety profile” and was “generally well tolerated,” the company added. The most common side effects were fatigue, headache, fever, and pain at the injection site.

Two shots soon ?

“We look forward to submitting the data to global regulatory agencies,” Moderna boss St├ęphane Bancel said in the statement.

The dose for children was adjusted to 50 micrograms, compared to 100 micrograms for injections for older age groups. This strength of 50 micrograms is also the one chosen for the adult booster dose, which has just been authorized in the United States.

These results mean that two vaccines may be available for young children in the near future. The American Medicines Agency (FDA) must indeed meet on Tuesday to study the application for authorization of Pfizer’s vaccine in children aged 5 to 11 years .

Moderna is also conducting parallel clinical trials on even younger children, between 6 months and 5 years old.

Back to top button